11-dehydro thromboxane b2 levels after percutaneous transluminal angioplasty in patients with peripheral arterial occlusive disease during a one year follow-up period

The aim of our study was to determine if the generation of thromboxane is altered in patients with peripheral arterial occlusive disease following percutaneous transluminal angioplasty (pta) during a one year follow-up period. in this study,175 patients diagnosed with peripheral arterial occlusive disease (paod) and demonstrating short-distance claudication or ischemic rest pain,requiring pta in either the iliac,femoral,or popliteal arteries,were enrolled. the excretion of 11-dehydro thromboxane b2 (txb2) was measured in urine samples by high-performance liquid chromatography-mass spectrometry and recalculated based on the creatinine concentration. the urine samples were collected the morning prior to pta,immediately following pta and the day after pta. all of the study subjects were then observed for a period of 12 months. urine samples were also collected during the follow-up visits,and the levels of 11-dehydro txb2were measured at 1 month (1458.1 pg/mg creatinine ± 1240.8),3 months (1623.3 pg/mg creatinine ± 1362.2),6 months (1314.8 pg/mg creatinine ± 1378.7) and 12 months (1473.2 pg/mg creatinine ± 1455.2) after the pta procedure. all of the patients were taking 75 mg of aspirin per day throughout the course of the study,as well as 75 mg of clopidogrel for six weeks following pta. overall,the mean txb2values immediately after pta were significantly higher than either before the procedure (1524.4 pg/mg creatinine ± 1411.1 vs. 2098.1 pg/mg creatinine ± 1661.8; p = 0.00002),the day after pta,or at any other point during the study. moreover,preoperative txb2levels correlated well with the composite endpoints of death,myocardial infarction and stroke during the follow-up period (or 7.42 [ci 95% = 1.2-48.8]; p = 0.02). our findings suggest that clinicians should consider the use of txa2synthase inhibitors and receptor antagonists in combination with peripheral percutaneous transluminal angioplasty in patients with peripheral arterial occlusive disease. © 2016,polish physiological society. all rights reserved.